Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
san francisco blog main
10
×
biotech
boston blog main
boston top stories
national top stories
san francisco top stories
raleigh-durham blog main
san diego blog main
san diego top stories
new york blog main
new york top stories
raleigh-durham top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
fda
startups
bristol-myers squibb
cancer
deals
intercept pharmaceuticals
medical device
nonalcoholic steatohepatitis
alnylam pharmaceuticals
avexis
cancer drugs
cancer immunotherapy
What
disease
10
×
drug
known
liver
medicines
nash
new
roundup
approved
bio
cancer
companies
established
fatty
fight
lung
medicine
news
race
therapy
according
adds
advanced
akcea
alliance
alnylam’s
alzheimer's
american
approval
areas
ash
bad
better
bff
big
biosciences
biotech
bio’s
blood
brain
Language
unset
Current search:
disease
×
" san francisco blog main "
×
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
5 years ago
California Life Sciences Fueled by Education, Established Companies
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On
@xconomy.com
6 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed